Compare ASTRAZENECA PHARMA with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs NOVARTIS - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA NOVARTIS ASTRAZENECA PHARMA/
NOVARTIS
 
P/E (TTM) x 141.2 2,243.4 6.3% View Chart
P/BV x 39.6 29.8 133.1% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 ASTRAZENECA PHARMA   NOVARTIS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
NOVARTIS
Mar-19
ASTRAZENECA PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,278980 130.4%   
Low Rs883600 147.1%   
Sales per share (Unadj.) Rs228.4198.7 114.9%  
Earnings per share (Unadj.) Rs10.421.0 49.4%  
Cash flow per share (Unadj.) Rs16.322.3 73.1%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs98.8307.5 32.1%  
Shares outstanding (eoy) m25.0024.69 101.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.0 119.0%   
Avg P/E ratio x104.237.7 276.6%  
P/CF ratio (eoy) x66.435.5 187.1%  
Price / Book Value ratio x10.92.6 425.7%  
Dividend payout %047.7 0.0%   
Avg Mkt Cap Rs m27,00819,508 138.4%   
No. of employees `0001.40.6 233.4%   
Total wages/salary Rs m1,5351,171 131.1%   
Avg. sales/employee Rs Th4,210.98,445.4 49.9%   
Avg. wages/employee Rs Th1,132.22,015.7 56.2%   
Avg. net profit/employee Rs Th191.1891.0 21.4%   
INCOME DATA
Net Sales Rs m5,7104,907 116.4%  
Other income Rs m123783 15.7%   
Total revenues Rs m5,8335,689 102.5%   
Gross profit Rs m463123 377.0%  
Depreciation Rs m14732 463.5%   
Interest Rs m016 0.0%   
Profit before tax Rs m438858 51.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179340 52.6%   
Profit after tax Rs m259518 50.0%  
Gross profit margin %8.12.5 323.9%  
Effective tax rate %40.839.6 103.0%   
Net profit margin %4.510.6 43.0%  
BALANCE SHEET DATA
Current assets Rs m3,2098,055 39.8%   
Current liabilities Rs m2,0701,850 111.9%   
Net working cap to sales %20.0126.4 15.8%  
Current ratio x1.64.4 35.6%  
Inventory Days Days7245 160.7%  
Debtors Days Days3534 103.0%  
Net fixed assets Rs m790150 527.6%   
Share capital Rs m50123 40.5%   
"Free" reserves Rs m2,4197,469 32.4%   
Net worth Rs m2,4697,592 32.5%   
Long term debt Rs m00-   
Total assets Rs m4,6059,824 46.9%  
Interest coverage xNM54.9-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.5 248.2%   
Return on assets %5.65.4 103.6%  
Return on equity %10.56.8 153.9%  
Return on capital %17.711.5 154.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30058 520.1%   
Fx outflow Rs m2,0151,326 151.9%   
Net fx Rs m-1,715-1,269 135.2%   
CASH FLOW
From Operations Rs m88-1,943 -4.5%  
From Investments Rs m-942,742 -3.4%  
From Financial Activity Rs mNA-298 0.0%  
Net Cashflow Rs m-6501 -1.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 0.3 2.0 15.0%  
FIIs % 15.7 1.6 981.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 21.5 42.3%  
Shareholders   12,856 41,647 30.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   FULFORD INDIA  VENUS REMEDIES  CIPLA  WOCKHARDT  AUROBINDO PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends at Record High; Tata Motors and Adani Ports Among Top Nifty Gainers(Closing)

Indian share markets extended gains to the second day today and ended at record-high levels with Nifty ending above 14,600-mark.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 20, 2021 03:36 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - UNICHEM LAB COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS